ArticleOpen forum infectious diseases2025
Emergence of Acquired HIV Drug Resistance Among Individuals Receiving Dolutegravir-Based Antiretroviral Therapy in Uganda: A National Laboratory-Based Survey 2023.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Advancements in development of novel class of HIV protease inhibitors.Annals of medicine · 2026Review
- Long-Acting Injectable Cabotegravir/Rilpivirine as a Second-Line ART Regimen for Pregnant and Breastfeeding Women in Kenya: Modeling the Potential Impact on Vertical Transmission.Open forum infectious diseases · 2026Article
- Machine Learning Identifies Potential Accessory Resistance-Associated Mutations in HIV-1 Integrase.Research square · 2026Article
- Article
- Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross-Sectional Survey.Journal of the International AIDS Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As dolutegravir (DTG)-based regimens (DBRs) become more widely used and patients remain on treatment longer, cases of virological failure remain rare. This study presents findings from the second annual round of acquired HIV drug resistance (HIVDR) surveillance in Uganda, among individuals with viral nonsuppression (≥1000 copies/mL) receiving DBRs for ≥9 months. The first round was conducted from February to April 2022. Methods: This nationally representative cross-sectional survey analyzed randomly selected remnant plasma and dried blood spot specimens collected between April and July 2023 from the Central Public Health Laboratories. Genotyping targeted the integrase, protease, and reverse transcriptase regions of the HIV-1 Results: Out of 857 specimens tested, 400 (46.7%) were from children and 457 (53.3%) from adults. Median ages were 11 years for children and 36 years for adults. Median time on DBRs was 1.9 years for children and 2.4 years for adults. Five hundred and fifty-nine (65.2%) specimens were successfully genotyped. The prevalence of DTG resistance was 10.1% (95% CI: 6.4%-13.9%) in children and 8.6% (95% CI: 3.9%-13.3%) in adult, higher than the first round with a prevalence of 6.6% (95% CI: 3.5%-9.6%) and 4.4% (95% CI: 0.7%-7.1%), respectively. Conclusions: The increase in DTG resistance among both children and adults highlights the need to strengthen adherence and enhance early identification of individuals at risk of HIVDR through novel and existing programmatic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.